Peto writes that "any competent trial statistician" would back his conclusions and says that Vytorin's makers, Merck and Schering-Plough, do not pay his salary and had no impact on the decision to conduct his analysis or on how the analysis was conducted (see Peto's letter).

FORBES: Magazine Article

In an interview, Peto argued that the cancer death issue is not statistically valid.

FORBES: Magazine Article

There, Richard Peto, an Oxford University statistician, quieted the cancer scare before it really began.

FORBES: Magazine Article